Download MendeleyPotent peptidic fusion inhibitors of influenza virus.
Kadam, R.U., Juraszek, J., Brandenburg, B., Buyck, C., Schepens, W.B.G., Kesteleyn, B., Stoops, B., Vreeken, R.J., Vermond, J., Goutier, W., Tang, C., Vogels, R., Friesen, R.H.E., Goudsmit, J., van Dongen, M.J.P., Wilson, I.A.(2017) Science 358: 496-502
- PubMed: 28971971
- DOI: https://doi.org/10.1126/science.aan0516
- Primary Citation of Related Structures:
5W5S, 5W5U, 5W6I, 5W6R, 5W6T, 5W6U - PubMed Abstract:
Influenza therapeutics with new targets and mechanisms of action are urgently needed to combat potential pandemics, emerging viruses, and constantly mutating strains in circulation. We report here on the design and structural characterization of potent peptidic inhibitors of influenza hemagglutinin. The peptide design was based on complementarity-determining region loops of human broadly neutralizing antibodies against the hemagglutinin (FI6v3 and CR9114). The optimized peptides exhibit nanomolar affinity and neutralization against influenza A group 1 viruses, including the 2009 H1N1 pandemic and avian H5N1 strains. The peptide inhibitors bind to the highly conserved stem epitope and block the low pH-induced conformational rearrangements associated with membrane fusion. These peptidic compounds and their advantageous biological properties should accelerate the development of new small molecule- and peptide-based therapeutics against influenza virus.
Organizational Affiliation:
Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
